BridgeMD
New treatment option for Cutaneous Leishmaniasis
Official title Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis
ClinicalTrials.gov ID: NCT06797544
What this study is testing
What is Levofloxacin 0.5%?
Levofloxacin 0.5% is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for cutaneous leishmaniasis.
Also referred to as Tavanic.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Aim of the study to evaluate the effectiveness of intralesional levofloxacin 0.5% solution as a local injection in treating cutaneous leishmaniasis. In an open-label single-arm clinical trial, all patients were given intralesional levofloxacin injections; the patients had cutaneous leishmaniasis lesions.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 6 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis and patients ranging in age from 20 to 75 years old.
You likely can't join if
- Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study and patients on prolonged...
The study team makes the final eligibility decision.
Where it's taking place
- Baghdad, Iraq
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 6 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baghdad, Iraq. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.